linjc16/ctgov huggingface dataset:
Association of Circulating Chemerin Levels and Arterial Stiffness

Study Overview
=================
Brief Summary
-----------------
Chemerin is a novel adipokine that might provide a link between chronic inflammation and obesity. Pulse wave velocity(PWV) is a useful method for examining arterial stiffness, meaning early-stage atherosclerosis. Therefore, in the present study, the investigators examined the relationship between circulating chemerin and arterial stiffness measured using PWV in obese persons.

Conditions
-----------------
Obesity, Atherosclerosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Self referred persons for visiting routine medical check in our clinic Exclusion Criteria: Malignancy Severe renal or hepatic disease

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Non- obese group<br> | |
| Obese group<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The difference of serum chemerin level between obese and non-obese groups | serum chemerin levels of all participants were by determined by an enzyme-linked immunosorbent assay (ELISA) kit (Biovender Laboratory Medicine Inc., Modrice, Czech Republic) | at the time of initial enrollment (4weeks) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The correlation of serum chemerin levels with arterial stiffness | Arterial stiffness was measure using a Colin Waveform Analyser (model BP-203RPE II; Colin, Komaki, Japan). It was expressed as branchial ankle pulswe wave velocity (baPWV) | at the time of enrollment (4 weeks) |
Cannabidiol for the Treatment of Severe (Grades III/IV) Acute Graft-versus-host Disease

Study Overview
=================
Brief Summary
-----------------
Graft-versus-host-disease (GVHD) is a major obstacle to successful allogeneic hematopoietic cell transplantation (alloHCT). Cannabidiol (CBD), a non-psychotropic ingredient of Cannabis sativa possesses potent anti-inflammatory and immunosuppressive properties. In a recent phase 2 study, CBD has been shown to be safe and reduced significantly the incidence of acute GVHD compared to control patients with a hazard ratio of 0.3. Based on these results the investigators propose a phase 2 study to explore the efficacy of oral CBD in the treatment of severe (grades III/IV) acute GVHD, a pathology with a dismal prognosis.

Official Title
-----------------
Cannabidiol for the Treatment of Severe (Grades III/IV) Acute Graft-versus-host Disease

Conditions
-----------------
Acute-graft-versus-host Disease

Intervention / Treatment
-----------------
* Drug: Cannabidiol
* Drug: Methylprednisolone
* Drug: Calcineurin inhibitor


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients 18 years or older After allogeneic transplantation Grade III or IV acute GVHD No psychiatric contra-indication Informed consent Exclusion Criteria: History of psychosis Asthma Known allergy to cannabis constituents

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Cannabidiol<br> | Drug: Cannabidiol<br>* Oral cannabidiol at a dose of 150 mg BID up to 90 days.<br>Drug: Methylprednisolone<br>* IV methylprednisolone 2 mg/kg/day<br>Drug: Calcineurin inhibitor<br>* cyclosporine with dose adjusted based on drug trough levels (200-400 ng/ml) or tacrolimus with dose adjusted on drug trough levels (5-15 ng/ml)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of patients with complete remission of acute GVHD |  | 90 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of patients with partial remission of acute GVHD |  | 90 days | 
| Proportion of patients with chronic GVHD |  | 12 months | 
| Proportion of patients able to discontinue immunosuppression |  | 12 months | 
| Transplant related mortality |  | 12 months |
Serum Markers of Ischemia Reperfusion Injury in Liver Transplant Patients

Study Overview
=================
Brief Summary
-----------------
This is an observational study examining serum markers in patients who are undergoing either a cadaveric liver transplant or a living related liver transplant.

Detailed Description
-----------------
The Departments of Anesthesiology are conducting an observational trial of markers in the serum of patients who are undergoing liver transplantation surgery. This study will utilize the biological markers, trimethylamine-N-oxide (TMAO), NGAL, and cystatin-C, sensitive markers of renal medullary injury in the blood and allantoin, a marker of oxidative stress as indicators of renal injury in a kidney during liver transplants. It is hypothesized that: (1) these markers are less pronounced in living donor liver transplant recipient patients than in cadaveric liver transplant recipients, and (2) these markers are less pronounced in cadaveric liver transplant recipients in which a piggy-back technique was used versus recipients in which a total venous occlusion technique was used. This study will be done in a multi-center format, along with researchers at UCSF

Official Title
-----------------
Serum Markers of Ischemia Reperfusion Injury in Liver Transplant Patients, Phase II

Conditions
-----------------
Liver Transplant

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: American Society of Anesthesiologists (ASA) Class I-V. Patient is undergoing elective Liver Transplant Surgery. Patient is an adult, 18 years old or older. Exclusion Criteria: Patients < 18 Years of Age Patients who are pregnant

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Live Donor | |
| 2<br>Cadaveric Donor | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
liver, transplant, TMAO, NGAL, cystatin-C, Ischemia Reperfusion Injury, Liver Transplant, LTx, allantion
Comparative Bioavailability Study of Codeine Sulfate

Study Overview
=================
Brief Summary
-----------------
The objective of this study was to assess the comparative bioavailability of codeine from Roxane Laboratories' Codeine Sulfate 30mg tablets to Tylenol® #3 (acetaminophen 300mg with codeine phosphate 30mg) under fasted conditions

Official Title
-----------------
A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Comparative Bioavailability Study fo Codeine 30 mg Tablets and Tylenol #3 Tablets Under Fasting Conditions

Conditions
-----------------
Pain

Intervention / Treatment
-----------------
* Drug: Codeine Sulfate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening. Exclusion Criteria: Positive test for HIV, Hepatitis B, or Hepatitis C. Treatment with known enzyme altering drugs. History of allergic or adverse response to codeine sulfate or any comparable or similar product.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Codeine Sulfate<br>30 mg tablet | Drug: Codeine Sulfate<br>* 30 mg Tablet<br>* Other names: Tylenol #3 Tablets;|
| Active Comparator: Tylenol #3<br>30 mg tablet | Drug: Codeine Sulfate<br>* 30 mg Tablet<br>* Other names: Tylenol #3 Tablets;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| bioequivalence determined by statistical comparison Cmax |  | 15 days |
Evaluation of Obstructive Sleep Apnea With Long Range 3D Endoscopic Fourier Domain Optical Coherence Tomography (FDOCT)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether the Optical coherence tomography (OCT) can image the structure and geometry of hollow organs of the upper airway in sleep disorder. The research can identify the obstruction sites that help the select the appropriate treatment for potential surgical candidates.

Detailed Description
-----------------
The National Commission on Sleep Disorders Research estimated that 18 million Americans suffer from obstructive sleep apnea (OSA) The majority of them are undiagnosed and untreated at this time. The current diagnostic gold standard for OSA is in-laboratory, a full night polysomnography (PSG). However, PSG is unable to provide information on upper airway structure and anatomy, and cannot identify the obstruction sites. OSA can lead to severe health complications including hypertension, heart failure, memory impairment, motor vehicle and work accidents, decreased work productivity, and increased risk of death.

Official Title
-----------------
Evaluation of Obstructive Sleep Apnea With Long Range 3D Endoscopic Fourier Domain Optical Coherence Tomography (FDOCT)

Conditions
-----------------
Sleep Apnea

Intervention / Treatment
-----------------
* Device: 3D endoscopic Fourier Domain OCT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or Female age 18-65 years has no history of obstructive sleep apnea Male or Female age 18-65 years has been diagnose of mild to moderate obstructive sleep apnea Male or Female age 18-65 years has been diagnose severe obstructive sleep apnea Exclusion Criteria: Pregnant women. Breastfeeding women. Unable to understand or give consent to the study. Currently taking drugs that are sensitive to light. Currently taking routine anti-convulsion, sedative or antihistamine drugs. Currently taking immuno-suppressive drug therapy.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: 3D endoscopic Fourier Domain OCT<br>3D endoscopic Fourier Domain OCT | Device: 3D endoscopic Fourier Domain OCT<br>* Evaluation of Obstructive Sleep Apnea<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| obstructive upper airways in sleep disordered | The OCT can provide information on upper airway structure and anatomy, and identify the obstruction sites. | 8 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
APNEA
REVEAL Study: Vessel Healing After Angioplasty

Study Overview
=================
Brief Summary
-----------------
To address early vessel healing and thrombus formation after deployment of three distinct groups of stents

Detailed Description
-----------------
A prospective, randomized study providing new evidences on early vessel healing and thrombus development after stenting with different devices.

Official Title
-----------------
Rapid Evaluation of Vessel HEaling After AngiopLasty (REVEAL) Trial: Rationale, Objectives and Design

Conditions
-----------------
Coronary Artery Disease

Intervention / Treatment
-----------------
* Device: Catania Stent


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Lesion length ≤ 20 mm Two significant short lesions Exclusion Criteria: Life expectancy < 1 year Left ventricular ejection fraction (LVEF) <30% Chronic kidney disease

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Stent<br>Catania Stent | Device: Catania Stent<br>* coronary stent implantation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| percentage of healed stent struts at 28-32 days |  | 30 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measurement of neointimal growth on stent struts |  | 30 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Coronary Stent
Intrabone Cord Blood Transplantation

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the viability of intrabone administration of umbilical cord blood as allogenic transplantation for the treatment of hematologic malignancies.

Official Title
-----------------
Pilot Study About Viability and Efficacy of Intrabone Administration of Umbilical Cord Blood for Allogeneic Stem Cell Transplantation

Conditions
-----------------
Hematological Malignancies

Intervention / Treatment
-----------------
* Procedure: Intrabone administration of umbilical cord blood


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hematological malignancies Indication of allogenic transplantation No suitable donor (related/unrelated) No suitable cord blood unit with enough cellularity for standard transplant Written informed consent Exclusion Criteria: ECOG > 2 Co-morbidities HIV positive serology Pregnancy or breastfeeding Psychiatric illness

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Cord blood<br> | Procedure: Intrabone administration of umbilical cord blood<br>* Single administration<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Kinetics of hematopoietic engraftment |  | days 14, 21, 28 after administration | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dynamics and chimerism of hematological engraftment |  | days 14, 21, 28 after administration |
Safety and Tolerability of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis (2-5 Years Old) (BY9010/M1-416)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the safety and tolerability of ciclesonide nasal spray for long term use in relieving symptoms in perennial allergic rhinitis.

Official Title
-----------------
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Clinical Trial Designed to Assess the Safety and Tolerability of Ciclesonide (200 mcg Once Daily), Applied as a Nasal Spray for Twelve Weeks, in the Treatment of Perennial Allergic Rhinitis (PAR) in Pediatric Patients 2-5 Years of Age

Conditions
-----------------
Hay Fever, Perennial Allergic Rhinitis

Intervention / Treatment
-----------------
* Drug: Ciclesonide


Participation Criteria
=================
Eligibility Criteria
-----------------
Main Inclusion Criteria: General good health, other than perennial allergic rhinitis History and diagnosis of perennial allergic rhinitis by skin prick test History of perennial allergic rhinitis for a minimum of 90 days immediately before the screening visit Main Exclusion Criteria: Participation in any investigational drug trial within the 30 days before the screening visit Use of any disallowed concomitant medications within the prescribed withdrawal periods before the screening visit A known hypersensitivity to any corticosteroid

Ages Eligible for Study
-----------------
Minimum Age: 2 Years
Maximum Age: 5 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Ciclesonide|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety and tolerability of ciclesonide nasal spray |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hay Fever, Allergic Rhinitis, Perennial Allergic Rhinitis, Ciclesonide
Delivery During Covid-19 Pandemic: Implications for Obstetrics, Maternal Psychopathology, and Mother-Infant Relationship

Study Overview
=================
Brief Summary
-----------------
The Coronavirus 2019 (COVID-19) pandemic has brought about unprecedented social, economic and mental-health challenges, especially for vulnerable populations such as pregnant and post-partum females. In this study, we aimed to evaluate the relations between the fear of COVID-19 and postnatal depression symptoms.

Detailed Description
-----------------
This is a multicenter prospective cohort study of childbearing women during COVID-19. Participants completed a comprehensive online questionnaire including demographic, socioeconomic, obstetric, and postnatal mental-health questionnaires. Data were verified with each center's perinatal database and information regarding physiological stress during pregnancy/birth was also collected. Fear of COVID-19 was evaluated using the validated Fear of COVID-19 Scale and postnatal depression was evaluated using the EPDS. Pre-existing maternal disability was defined as prior physiological or psychological chronic health condition.

Official Title
-----------------
Delivery During Covid-19 Pandemic: Implications for Obstetrics, Maternal Psychopathology, and Mother-Infant Relationship in the Shadow of a Socioeconomic Crisis

Conditions
-----------------
Delivery; Trauma, Covid19

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: women who delivered during the Covid-19 pandemic at the site, since 01-March-2020 Exclusion Criteria: women age 18 and below Gestational age under 34 weeks Intra Uterine Fetal Demise Ante-partum Fetal Demise Maternal post partum death

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of COVID-19 during pregnancy | Fear of COVID-19 was evaluated using the validated Fear of COVID-19 Scale | 1 year after delivery | 
| The relations between fear of COVID-19 and postnatal depression symptoms. | Postnatal depression was evaluated using the EPDS. | 1 year after delivery |
Glycaemic Responses to Cracker Snacks

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether added ingredient affects glycaemic responses to a cracker snack.

Official Title
-----------------
Effects of Added Spice Flour on Glycaemic Responses to a Cracker Snack

Conditions
-----------------
Glycaemic Response Measurements

Intervention / Treatment
-----------------
* Other: Control Cracker Snack
* Other: Experimental Cracker Snack 1
* Other: Experimental Cracker Snack 2


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female (not less than 40% Male) Aged 18 - 55 years Non Smokers Have a body mass index between 18.5 to 29.99 kg/m2 Healthy, non-diabetic, no gastric bypass surgery Not allergic to wheat, mustard, dairy, or soy Have a fasting plasma glucose (finger-stick) <100 mg/dl (<5.5 mmol/L) Willing and able to provide written informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Control Cracker<br>Base cracker snack | Other: Control Cracker Snack<br>* Base cracker snack<br>|
| Experimental: Experimental Cracker Snack 1<br>Cracker snack containing test ingredient 1 | Other: Experimental Cracker Snack 1<br>* Cracker snack containing test ingredient 1<br>|
| Experimental: Experimental Cracker Snack 2<br>Cracker snack containing test ingredient 2 | Other: Experimental Cracker Snack 2<br>* Cracker snack containing test ingredient 2<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Glycaemic Response(s) to cracker snacks as measured by incremental Area Under the Curve (iAUC) | The endpoint will be the blood glucose response curve, calculated from the individual glucose measurements. Evaluated by repeated measures ANOVA on incremental AUC measured in capillary blood. | 120 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Glycaemic Response